Personalized Approaches to Sustained Biologic Remission in CROHN'S DISEASE-Mobile, AL
This initiative has been designed to increase knowledge and competence and the participant’s ability to:
1. Increase the frequency of colonoscopy or other imaging modalities prior to and following the initiation of a biologic therapy in patients with CD
2. Increase the utilization of mucosal healing as a therapeutic endpoint in clinical practice
1. Introductory Remarks
2. Endoscopy for the Assessment of Mucosal Healing
a. The relationship between endoscopic improvement and treatment outcomes
b. Endoscopic disease scoring scales in CD
c. The relationship between treatment and achievement of mucosal healing
3. Novel Techniques to Assess Mucosal Healing: Radiology & Biomarkers
b. Capsule Endoscopy
c. C-reactive protein
4. Individualizing Therapy for Patients with Crohn’s Disease
a. Symptoms relief vs. endoscopic findings
b. Prognostic stratification
c. Therapeutic drug monitoring
d. ‘Step-up’ vs ‘Top-down’ treatment approaches
5. Concluding Remarks and Audience Q & A
Acknowledgement of Commercial Support
This activity is supported by independent educational grants from AbbVie, Prometheus, and UCB, Inc.
These activities have been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of patients with Crohn’s disease (CD).
At the conclusion of these activities, participants will be able to:
- Discuss the clinical benefits of mucosal healing in patients with CD
- Design an effective treatment plan that maximizes the occurrence of mucosal healing in patients with CD
- Evaluate the clinical utility of colonoscopy, non-invasive imaging techniques, and biomarkers for the assessment of mucosal healing in patients with CD
David T. Rubin, MD, FACG, AGAF, FACP
The Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology and Nutrition
The University of Chicago Medicine
William J. Sandborn, MD
Professor of Medicine and Adjunct Professor of Surgery
Chief, Division of Gastroenterology
Director, UCSD IBD Center
University of California, San Diego and UC San Diego
La Jolla, CA
Jack A. Di Palma, MD
Professor of Medicine
Director, Division of Gastroenterology
University of South Alabama College of Medicine
Dr. Di Palma trained in medicine at New York Medical College, Valhalla, New York and did a residency in Internal Medicine at USAF Medical Center, Keesler, Biloxi, Mississippi. After completing his fellowship in gastroenterology at Wilford Hall USAF Medical Center in San Antonio, Texas, he served on their teaching faculty. In 1987, Dr. Di Palma established the Division of Gastroenterology at the University of South Alabama which he still directs.
Dr. Di Palma's scholarly interests are in various areas of digestive disorders and physiology. He has contributed over 350 published articles, reviews, book chapters and abstracts. Dr. Di Palma directs the gastroenterology fellowship training program and the division is known for teaching to medical students, residents, physician's assistants and nurse practitioners. He was recognized as “Best Clinical Teacher” by the 1996 College of Medicine students and by “Best Doctors” in “Mobile/Baldwin counties”, “Alabama” and “America.” The USA Gastroenterology Division was voted the best clinical elective in 1998 by the medical students.
Dr. Di Palma is active in the gastroenterology associations and organized medicine. He served on the Board of Censors of the Medical Society of Mobile County and was the Chairman of the Mobile County Board of Health. Dr. Di Palma is the Past-President of the American College of Gastroenterology. He is currently the Treasurer of the Foundation Board of the World Gastroenterology Organization.
Bincy P. Abraham, M.D., M.S.
Director, Fondren IBD Program at the
Underwood Center for Digestive Disorders
Houston Methodist Hospital
Dr. Abraham is the director of the Fondren Inflammatory Bowel Disease Program at the David Underwood Center for Digestive Disorders at Houston Methodist Hospital. Dr. Abraham earned her medical degree from University of Texas Medical Branch, Galveston, TX, where she continued with residency training in internal medicine and fellowship in gastroenterology. During fellowship, she received specialized training in inflammatory bowel disease and earned her degree in Masters of Clinical Investigation. She also completed a National Visiting Fellow Inflammatory Bowel Disease Rotation program through the Crohn’s and Colitis Foundation of America in Cedars Sinai Hospital in Los Angeles. Her particular interest in inflammatory bowel
disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She also directs the Gastroenterology Fellowship program at Houston Methodist.
Faculty Financial Disclosure Statements
The planning committee and presenting faculty reported the following:
Dr. Sandborn is a consultant for AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Pfizer, Genentech, Amgen and Receptos. He has received grant support from AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Pfizer, Genentech, Amgen, and Receptos.
He does not hold stock options in these companies.
Dr. Sandborn is not a member of speaker bureaus or advisory boards.
Dr. Rubin is a consultant for AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Pfizer, Genentech, Amgen, Prometheus Laboratories, Shire, Emmi, Telsar Pharmaceuticals, and Santauras/Salix. He has received grant support from AbbVie, Janssen, UCB Pharmaceuticals, Takeda, Genentech, Prometheus Laboratories, and Shire.
Dr. Rubin is not a member of speaker bureaus or advisory boards.
He does not hold stock options in these companies.
Dr. Di Palma is a promotional speaker for Janssen.
He does not hold stock in Janssen.
Dr. Abraham is on the advisory boards for Janssen, UCB Pharmaceuticals, and Takeda. She is also a consultant for Celgene, and is a speaker for AbbVie, Prometheus and Salix.
Dr. Abraham does not hold stock or options for these companies.
Education Partner Financial Disclosure Statements
Faculty and staff involved in the planning and review of this activity have nothing to disclose.
As a provider accredited by the Accreditation Council for Continuing Medical Education’s (ACCME), The University of Chicago Pritzker School of Medicine requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, which could create a conflict of interest.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
In compliance with the ACCME updated accreditation criteria, presentations of those with reported potential conflicts were reviewed prior to presentation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of The University of Chicago Pritzker School of Medicine, FACTORx, and MedEd Consulting. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.